LTR Pharma Limited (ASX:LTP)
Australia · Delayed Price · Currency is AUD 0.4600
+0.0250 (5.75%)
At close: Mar 10, 2026
LTR Pharma Revenue
LTR Pharma had revenue of 73.75K AUD in the half year ending December 31, 2025. This brings the company's revenue in the last twelve months to 1.13M, up 126.42% year-over-year. In the fiscal year ending June 30, 2025, LTR Pharma had annual revenue of 1.51M with 2,978.25% growth.
Revenue (ttm)
1.13M
Revenue Growth
+126.42%
P/S Ratio
73.90
Revenue / Employee
n/a
Employees
n/a
Market Cap
83.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.51M | 1.46M | 2,978.25% |
| Jun 30, 2024 | 49.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 9.08K | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 16.28M |
| Alterity Therapeutics | 6.64M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
| Prescient Therapeutics | 4.27M |
| Imugene | 3.94M |
| Arovella Therapeutics | 3.21M |
| Proteomics International Laboratories | 3.21M |